How Exercise Boosts Cancer Immunotherapy: The Role of Gut Microbes and Formate
/0 Comments/in Not PCa related/by MaxATRN-119: A New Promising ATR Inhibitor for ATM Mutations (And Other HRR Mutations)
/0 Comments/in Not PCa related/by MaxZebrafish Embryo miRNAs: A Potential New Approach to Slow or Stop Cancer Spread
/0 Comments/in Not PCa related, Preclinical Research/by MaxCRISPR is Here to Stay: Gene Therapy Succesfully Used On An Infant With Incurable Disease
/0 Comments/in Not PCa related/by MaxPrecision in Action: How Logic-Gating Redefines Targeted Therapy
/0 Comments/in Not PCa related/by MaxOrally Delivered CRISPR Therapy, Groundbreaking Evolution
/0 Comments/in CRISPR, Not PCa related, Preclinical Research/by MaxA New Compound Looks Promising for Bone Metastasis
/0 Comments/in Not PCa related, Preclinical Research/by MaxHydrogel Breakthrough May Improve Cancer Vaccines
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer August 30, 2025
- Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN) August 29, 2025
- Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer August 29, 2025
- Phase 1: Lartesertib and Tuvusertib Target DNA Repair to Fight Resistant Tumors August 29, 2025